Quick Answer
ProMIS Neurosciences Inc. reported Operating Income Loss of -$40.17 million for the year ending 2025.
- ProMIS Neurosciences Inc. showed a decrease of -138.7% in Operating Income Loss from 2024 to 2025.
- This data is from ProMIS Neurosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: -$1.11 million | Q3 2021: -$2.07 million | Q1 2022: -$3.94 million | Q2 2022: -$4.86 million | Q3 2022: -$6.05 million | Q1 2023: -$4.97 million | Q2 2023: -$2.90 million | Q3 2023: -$2.52 million | Q1 2024: -$3.68 million | Q2 2024: -$2.71 million | Q3 2024: -$4.43 million | Q1 2025: -$7.46 million | Q2 2025: -$10.18 million | Q3 2025: -$11.75 million.
- Over the full 5 years of available data (2021 to 2025), ProMIS Neurosciences Inc.'s Operating Income Loss has declined by 384.5%.
- Historical annual values: Fiscal year 2025: -$40.17 million | Fiscal year 2024: -$16.83 million | Fiscal year 2023: -$14.26 million | Fiscal year 2022: -$23.38 million | Fiscal year 2021: -$8.29 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: